Skip to main navigation
Aligos Therapeutics Logo

    Investor Relations

  • Overview
  • Stock
    Stock Quote & Chart Analyst Coverage
  • News & Events
    News Releases Investor Calendar Presentations
  • Financials
    SEC Filings Quarterly Results
  • Governance
    Governance Highlights Committee Composition
  • Resources
    Investor FAQs Email Alerts Contact IR

News Releases

Jan 05, 2023
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
– Final cohort of Phase 1 study projected to be complete in H1 2023 – – Phase 2-enabling GLP toxicology studies projected to be complete in H2 2023 – – Clinical update on all pipeline programs to be presented at the 2023 J.P. Morgan Healthcare Conference on January 12 at 10:30 a.m.

Shareholder Tools

  • Print Page
  • Email Alerts
  • RSS
  • Investor FAQs
  • © Aligos Therapeutics 2023